We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+3.27%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.23B
AUM Growth
+$298M
(+4.3%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
2.07%
Top 10 Holdings %
Top 10 Hldgs %
15.39%
Holding
1,100
New
151
Increased
415
Reduced
333
Closed
164
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$40.6M |
| 2 |
Autodesk
ADSK
|
+$38.8M |
| 3 |
Intuit
INTU
|
+$37.1M |
| 4 |
Ecolab
ECL
|
+$35.6M |
| 5 |
Coca-Cola
KO
|
+$35.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$51.9M |
| 2 |
EOG Resources
EOG
|
+$33.8M |
| 3 |
DATA
Tableau Software, Inc.
DATA
|
+$32M |
| 4 |
Microsoft
MSFT
|
+$29.8M |
| 5 |
Ford
F
|
+$29.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.67% |
| 2 | Financials | 17.68% |
| 3 | Consumer Discretionary | 13.74% |
| 4 | Industrials | 11.53% |
| 5 | Healthcare | 11.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Shore Bancshares
SHBI
$790M
| $236K | ﹤0.01% |
14,436
+3,750
| +35% | +$58.5K |
|
|
AVP
852
DELISTED
Avon Products, Inc.
AVP
| $235K | ﹤0.01% |
60,600
-1,782,689
| -97% | -$5.94M |
|
853
Seres Therapeutics
MCRB
$48M
| $233K | ﹤0.01% |
3,614
-6,205
| -63% | -$589K |
|
|
FPRX
854
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $231K | ﹤0.01% |
38,260
-29,687
| -44% | -$284K |
|
855
Blackbaud
BLKB
$1.5B
| $230K | ﹤0.01% |
2,760
-12,047
| -81% | -$955K |
|
|
PDCE
856
DELISTED
PDC Energy, Inc.
PDCE
| $230K | ﹤0.01% |
+6,380
| New | +$241K |
|
857
Northeast Bank
NBN
$1.11B
| $228K | ﹤0.01% |
8,258
-5,058
| -38% | -$107K |
|
|
RNET
858
DELISTED
RigNet, Inc.
RNET
| $228K | ﹤0.01% |
+22,594
| New | +$209K |
|
|
CSS
859
DELISTED
CSS Industries, Inc.
CSS
| $226K | ﹤0.01% |
46,366
+3,841
| +9% | +$22.4K |
|
860
Chemung Financial Corp
CHMG
$390M
| $225K | ﹤0.01% |
+4,651
| New | +$222K |
|
861
PTC Therapeutics
PTCT
$6.37B
| $225K | ﹤0.01% |
+5,010
| New | +$198K |
|
|
LEAF
862
DELISTED
Leaf Group Ltd.
LEAF
| $224K | ﹤0.01% |
30,209
-54,285
| -64% | -$418K |
|
863
Aviat Networks
AVNW
$262M
| $223K | ﹤0.01% |
32,494
| – | – |
|
864
Corvus Pharmaceuticals
CRVS
$1.1B
| $223K | ﹤0.01% |
+59,718
| New | +$234K |
|
|
AE
865
DELISTED
Adams Resources & Energy Inc
AE
| $221K | ﹤0.01% |
+6,434
| New | +$226K |
|
|
CPRX
866
DELISTED
Catalyst Pharmaceutical
CPRX
| $217K | ﹤0.01% |
56,400
+1,500
| +3% | +$6.48K |
|
867
SouthState Bank Corp
SSB
$10.3B
| $217K | ﹤0.01% |
+2,950
| New | +$212K |
|
|
FOLD
868
DELISTED
Amicus Therapeutics
FOLD
| $215K | ﹤0.01% |
+17,200
| New | +$218K |
|
|
DNKN
869
DELISTED
Dunkin' Brands Group, Inc.
DNKN
| $215K | ﹤0.01% |
+2,700
| New | +$205K |
|
|
LTC
870
LTC Properties
LTC
$2.16B
| $213K | ﹤0.01% |
4,660
| – | – |
|
871
Essex Property Trust
ESS
$18.9B
| $211K | ﹤0.01% |
+724
| New | +$209K |
|
872
Larimar Therapeutics
LRMR
$416M
| $211K | ﹤0.01% |
14,795
+9,217
| +165% | +$246K |
|
|
ARC
873
DELISTED
ARC Document Solutions, Inc.
ARC
| $210K | ﹤0.01% |
102,888
+9,798
| +11% | +$21.4K |
|
874
Northrim BanCorp
NRIM
$603M
| $208K | ﹤0.01% |
23,304
-49,400
| -68% | -$428K |
|
|
MACK
875
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $208K | ﹤0.01% |
43,772
+12,887
| +42% | +$61.1K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2019 Portfolio in Review
As of Q2 2019, Jacobs Levy Equity Management held 1,100 positions worth $7.23B, up 4.3% from $6.93B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Jacobs Levy Equity Management's Q2 2019 filing shows 151 new, 415 increased, 333 reduced and 164 closed positions. Its largest new stake was Biogen: 175,817 shares worth $41.1M. The largest sale was Allergan plc, an estimated $51.9M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q2 2019 buy was Biogen: 175,817 shares worth $41.1M.
- Jacobs Levy Equity Management added most to Ecolab in Q2 2019, an estimated $35.6M increase.
- Jacobs Levy Equity Management's biggest Q2 2019 reduction was EOG Resources, cutting an estimated $33.8M.
- Jacobs Levy Equity Management fully exited Allergan plc in Q2 2019, selling an estimated $51.9M.
- Jacobs Levy Equity Management's ten largest holdings make up 15% of its $7.23B portfolio in Q2 2019.
- Jacobs Levy Equity Management opened 151 new positions and closed 164 in Q2 2019.
- Jacobs Levy Equity Management's portfolio value rose 4.3% quarter-over-quarter to $7.23B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2019, filed 13 Aug 2019.